JR-141
Sponsors
Jcr Pharmaceuticals Co. Ltd., JCR Pharmaceuticals Co., Ltd.
Conditions
Hunter SyndromeMucopolysaccharidosis IIMucopolysaccharidosis type IIMucopolysaccharidosis type II
Phase 1
Phase 2
A Study of JR-141 in Patients With Mucopolysaccharidosis II (BR21)
CompletedNCT03359213
Start: 2018-07-26End: 2019-10-04Updated: 2025-07-24
A Study of JR-141 in Patients With Mucopolysaccharidosis II
CompletedNCT03568175
Start: 2018-08-01End: 2020-02-20Updated: 2022-11-14
An Extension Study of JR-141-BR21 in Patients With Mucopolysaccharidosis II
Active, not recruitingNCT03708965
Start: 2019-01-01End: 2027-12-31Updated: 2026-09-08
An Extension Study of JR-141 in Patients With Mucopolysaccharidosis Type II
Active, not recruitingNCT04348136
Start: 2019-09-01End: 2030-03-31Updated: 2026-09-03
Phase 3
A Phase III Study of JR-141 in Patients With Mucopolysaccharidosis II (STARLIGHT)
Active, not recruitingNCT04573023
Start: 2022-02-14End: 2027-10-31Updated: 2026-06-04
An Extension Study of JR-141 to Evaluate the Long-term Safety and Efficacy in MPS II (Hunter Syndrome) Subjects
Enrolling by invitationNCT05594992
Start: 2023-02-22End: 2028-02-28Target: 80Updated: 2026-01-21
An Extension Study of JR-141 to Evaluate the Long-term Safety and Efficacy in Mucopolysaccharidosis Type II (Hunter Syndrome) Subjects
RecruitingCTIS2022-503142-41-00
Start: 2024-05-06Target: 32Updated: 2025-09-30
A PHASE III STUDY OF JR-141 IN MUCOPOLYSACCHARIDOSIS TYPE II (HUNTER SYNDROME) PATIENTS
Active, not recruitingCTIS2024-512289-33-00
Start: 2022-08-24Target: 35Updated: 2025-11-13